Acute Infection and Early Disease Research Program (AIEDRP)
Principal Investigator : Martin Markowitz, M.D.
[back to Clinical Trials]

1. What is the program?
This is an NIH-funded national program that studies newly acquired HIV-1 infection. We are one of 5 sites funded nationwide. Other sites are located in Boston, San Francisco, San Diego, Birmingham and Los Angeles. In addition there are subsites in Australia, Zambia and other areas in the U.S. The Aaron Diamond AIDS Research Center is the only AIEDRP site in the NYC Metropolitan area.
2. Who is eligible?
Patients who are within 1 year of acquiring HIV-1 infection.
3. How is eligibility determined?
Free and confidential testing is available at the Aaron Diamond AIDS Research Center (ADARC) and at our 2 subsites, Columbia University and State University of New York at Downstate Medical Center.
There are 3 basic categories:
Very early infection: A positive HIV-1 RNA test and a negative or indeterminate antibody test.
Early infection: a newly positive antibody test and a positive HIV-1 RNA test with a negative detuned HIV antibody test.
New Infection: A newly positive antibody test and a documented negative antibody test within 12 months of screening.
4. What does the program entail?
Newly infected individuals will be offered participation in a variety of studies that range from observation with no treatment to antiviral therapy and immune therapies. Specific trials are posted on this website. (Clinical trials)
5. How can patients be screened?
If you are seeing a patient that is symptomatic and undiagnosed or fits any of the above categories, you may refer the patient to one of the sites listed above by calling:
Manhattan and Queens: ADARC: 212-327-7290 or 917-584-8814
Brooklyn or Staten Island: S.U.N.Y. Downstate Medical Center: 917-760-0753
Bronx and Northern Manhattan: Columbia University: 917-899-8414
Contact the Aaron Diamond AIDS Research Center at 212-327-7290 or 917-584-8814 if there are problems reaching any of the above numbers or email dgarmon@adarc.org
6. What are the patient incentives?
	Participation will allow for careful monitoring of viral load and CD4 at no charge
	as well asresistance testing
	For specific studies medications may be free of charge.
	For patients without resources medications may be provided until assistance via ADAP
	or Medicaid can be arranged.
	Reimbursement for public transportation and child-care is available.
7. What are the scientific goals of the program?
	To establish whether early treatment is beneficial.
	To determine optimal duration of treatment.
	To understand determinants of virologic setpoint.
	To test whether patients can be treated with finite periods of HAART with
	immune therapies.
	To monitor the transmission of drug-resistant HIV-1.
8. How can I get more information about AIEDRP?
On the web at aiedrp.fhcrc.org or by email via dgarmon@adarc.org